Organon & Co | OGN - Current Liabilities



Organon & Co reported $2.8B in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
Adcock Ingram Holdings ZAR 2.81B 279.84M Dec/2024
Bristol-Myers Squibb USD 27.53B 3.46B Jun/2025
Celltrion KRW 3.4T 216.25B Mar/2025
Cspc Pharmaceutical CNY 9.63B 801.28M Dec/2024
Dianthus Therapeutics USD 20.09M 1.64M Jun/2025
Divis Laboratories Ltd 14.52B 1.61B Mar/2025
Gilead Sciences USD 11.19B 1.15B Jun/2025
Glaxosmithkline GBP 20.38B 1.32B Jun/2025
Kangmei Pharma CNY 5.75B 64.58M Jun/2025
Knight Therapeutics CAD 118.15M 12.32M Sep/2024
Laboratorios Farma EUR 186.51M 29.86M Jun/2025
Malin Corporation EUR 1000K 500K Dec/2024
Medical Developments International AUD 6.37M 3.17M Dec/2024
Merck USD 26.04B 863M Jun/2025
Neuren Pharmaceuticals AUD 45.76M 36.79M Dec/2024
Novartis USD 31.71B 3.02B Jun/2025
Organigram Holdings CAD 107.28M 38.32M Jun/2025
Organon & Co USD 2.8B 181M Jun/2025
Pharma Mar EUR 87.78M 8.29M Jun/2025
Qiagen NV USD 1.13B 611.37M Jun/2025
Sartorius EUR 1.55B 72.7M Jun/2025
Sino Biopharmaceutical CNY 19.56B 2.39B Dec/2024
Tilray USD 278.52M 15.02M Nov/2024